Program
Poliovirus Vaccine, Inactivated
Also written as “sIPV”, “IPV” and “Poliorix™”.
Its studies are mostly in Poliomyelitis · Gastroenteritis · Streptococcal Infections · Tetanus, led by 7 companies.
Drug pagePoliovirus Vaccine, Inactivated: every studyMany companies study it; this page follows only the 16 they lead. All 27 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 50 open or running | phase 3since Oct 19, 2007 | Oct 19, 2007 | none ahead |
| Sinovac Biotechits history only | 41 open or running | phase 4since Jan 29, 2024 | May 4, 2018 | none ahead |
| Beijing Minhai Biotechnologyits history only | 20 open or running | phase 3since Dec 12, 2024 | Dec 12, 2024 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 2since Jun 12, 2018 | Jan 24, 2017 | none ahead |
| E-MO Biologyits history only | 10 open or running | phase 4since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| Sinopharmits history only | 10 open or running | phase 4since Aug 8, 2019 | Aug 8, 2019 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Mar 24, 2017 | Mar 24, 2017 | none ahead |
Also a collaborator on its studies: Beijing Institute of Biological Products.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2007First study: phase 3 study in Streptococcal InfectionsFirst studyNCT00547248 · 756 enrolled · Philippines, Poland
- Jul 9, 2009Phase 1 study in PoliomyelitisNCT00937404 · 25 enrolled · China
- Nov 25, 2009Phase 3 study in PoliomyelitisNCT01021293 · 1,101 enrolled · China
- Oct 6, 2011Phase 3 study in TetanusNCT01449812 · 831 enrolled · China
- Mar 19, 2024Phase 3 study in GastroenteritisNCT06331156 · 400 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis”NCIt, by rule
Studies
All 5 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06331156Gastroenteritis · China | 3 | Completed | Oct 22, 2024 | 400 |
| NCT01449812Tetanus · China | 3 | Completed | Jan 16, 2012 | 831 |
| NCT01021293Poliomyelitis · China | 3 | Completed | Jul 5, 2010 | 1,101 |
| NCT00937404Poliomyelitis · China | 1 | Completed | Nov 13, 2009 | 25 |
| NCT00547248Streptococcal Infections · Philippines, Poland | 3 | Completed | May 10, 2008 | 756 |
How it is read
Names in the registry
- “sIPV”, 6 entries
- “IPV”, 3 entries
- “Poliorix™”, 2 entries
- “Poliorix”, 2 entries
- “sIPV+bOPV”, 1 entry
Conditions, from the studies’ own filings
- Poliomyelitis, 9 studies
- Gastroenteritis, 2 studies
- Streptococcal Infections, 1 study
- Tetanus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.